Is Lamotrigine (Lamictal) Safe with Ketamine?

Lamotrigine (Lamictal) is one of the more interesting medications to discuss in the context of at-home ketamine therapy. The pharmacology question itself is settled: the combination is safe, with no documented case reports of harm and no recommended washout. The clinically interesting question that does persist is whether lamotrigine attenuates ketamine's effects, a hypothesis that emerged from older pretreatment studies in healthy volunteers and that the most recent real-world clinical data has largely failed to confirm. As with Lithium, the case-by-case verdict reflects what lamotrigine signals about your underlying clinical picture rather than concern about the drug combination itself.

The pharmacology and the attenuation question

Lamotrigine is an antiepileptic medication that also functions as a mood stabilizer in bipolar disorder. Its primary mechanism is voltage-gated sodium channel blockade, which reduces neuronal excitability and, importantly, reduces presynaptic glutamate release. Ketamine works on the NMDA glutamate receptor; its antidepressant cascade depends on a downstream surge of glutamate signaling, AMPA receptor activation, and BDNF release.

The theoretical concern that emerged in the early 2000s was reasonable: if lamotrigine reduces glutamate release at the source, could it dampen ketamine's glutamate-driven antidepressant action at the receptor level? The hyperglutamatergic hypothesis was specifically tested in a 2000 study by Anand and colleagues (PMID 10711913), which gave 300 mg of lamotrigine to 19 healthy volunteers before a ketamine infusion. The lamotrigine pretreatment did reduce ketamine's dissociative symptoms (measured by CADSS) and reduced psychotomimetic effects (measured by BPRS), and altered ketamine's effect on BOLD signal in fMRI. Notably, lamotrigine also increased ketamine's immediate mood-elevating effects rather than blocking them. The interpretation in 2000 was that lamotrigine selectively dampens the unwanted dissociative effects of ketamine while preserving (or enhancing) the desired mood effects.

This finding led to further investigation in actual depression patients, which is where the clinical question gets interesting.

What the patient-population evidence actually shows

The 2021 Veraart systematic review (International Journal of Neuropsychopharmacology, PMID 34170315) examined seven studies on lamotrigine + ketamine. The pattern that emerged is mixed: three studies supported the attenuation hypothesis (lamotrigine reduced ketamine's dissociative effects, particularly in pretreatment paradigms), and four studies did not confirm an interaction. The authors' summary was honest: "Some but not all studies on lamotrigine provided evidence for attenuation of ketamine-induced effects." No case reports of harm were identified.

The most direct and recent answer comes from Santucci and colleagues' 2025 real-world cohort study in Psychopharmacology (PMID 40973876). This is the largest study to date specifically examining the lamotrigine question in actual depression patients treated with ketamine or esketamine. They followed 347 patients with unipolar major depressive disorder at Yale Psychiatric Hospital from 2014 through 2023, of whom 57 were concurrently on lamotrigine. They measured MADRS and QIDS depression scores over time and looked for a group-by-time interaction (the statistical test for whether lamotrigine changes the trajectory of ketamine response). Their finding was clean: no interaction in the unadjusted model, no interaction after adjusting for multiple confounders. Their conclusion: "We found no clinical evidence for an interaction between lamotrigine and treatment with ketamine/esketamine in a real-world sample of treatment-seeking patients with major depressive disorder."

This is meaningful for the clinical question. The pretreatment finding in healthy volunteers (300 mg lamotrigine acutely loaded before a single ketamine infusion) is a different scenario than the chronic-treatment reality (patients on stable maintenance lamotrigine for months or years who add a course of ketamine on top). At therapeutic chronic doses, in actual depression patients, the attenuation predicted by the pharmacology has not materialized in measurable clinical outcomes. The Veraart 2021 conclusion that the evidence is mixed and the Santucci 2025 finding of no clinical interaction in real-world use together support continuing lamotrigine throughout the ketamine course without expecting it to interfere.

Why the verdict is case-by-case despite the safety being settled

If the combination is safe and the attenuation concern hasn't borne out, why isn't this a ✅ SAFE verdict like Lexapro or Zoloft? Two reasons.

Different patient contexts under one medication. Lamotrigine is prescribed for three quite different clinical pictures, and each gets a slightly different intake conversation:

For bipolar I or II depression on lamotrigine for mood stabilization, the ketamine conversation is the same nuanced one we have with bipolar patients on lithium: continuing the mood stabilizer is the right move (it actively reduces manic-switch risk during ketamine therapy), but the underlying bipolar context means closer-monitored care may be appropriate for some patients, and coordination with the treating psychiatrist is important.

For epilepsy on lamotrigine for seizure control, the conversation centers on continuing seizure prophylaxis without interruption. Ketamine at therapeutic at-home doses has an anticonvulsant rather than pro-convulsant profile (Shehata et al. 2024 systematic review of 30 studies; 26 supporting antiepileptic properties), so the combination doesn't compound seizure risk. The important step is not stopping lamotrigine for any ketamine-related reason; we coordinate with the prescribing neurologist.

For unipolar treatment-resistant depression where lamotrigine has been added as an augmentation strategy, the conversation looks like any TRD patient's. Lamotrigine continues, ketamine is added, and the most recent real-world evidence supports the combination without expectation of attenuation.

The verdict is case-by-case because the conversation differs across these three subgroups, not because the lamotrigine + ketamine combination is itself complicated.

The honest acknowledgment that the attenuation question isn't fully closed. While the Santucci 2025 real-world data is reassuring, individual patients vary, and the Veraart 2021 review's mixed findings reflect real heterogeneity in how patients respond. For most patients lamotrigine will not change anything about their ketamine response. For some patients there may be a subtle reduction in the dissociative experience (which most patients would welcome) and possibly a subtle change in antidepressant trajectory (which the population-level data does not detect but which an individual patient might notice). We don't promise that lamotrigine will or won't change your specific response; we tell you the evidence honestly and proceed with standard onboarding.

Bipolar depression on lamotrigine: the detailed conversation

If you're on lamotrigine for bipolar disorder (I, II, or schizoaffective with bipolar features), the ketamine conversation is structurally similar to the one we have with bipolar patients on lithium. The Fancy et al. 2023 systematic review in Therapeutic Advances in Psychopharmacology synthesized what's known about ketamine in bipolar depression: pooled response rates around 48% in trials, real-world response rates somewhat lower (around 30%), manic or hypomanic switch rates approximately 2% across studies. The switch rate is meaningfully reduced when patients remain on a mood stabilizer like lamotrigine during the ketamine course, and real-world esketamine + mood stabilizer data shows no increased manic-switch risk versus depression-only populations on equivalent treatment.

At intake for a bipolar patient on lamotrigine we confirm:

The type of bipolar disorder. Bipolar I patients tend to get a more detailed conversation about closer monitoring for the loading phase. Bipolar II and schizoaffective with bipolar features are usually managed more like standard onboarding.

Recent mood-episode history. Recent manic, hypomanic, or mixed episodes in the past 12 months are a flag for closer monitoring rather than an automatic contraindication.

Current mood stability and the relationship with your treating psychiatrist. For most bipolar patients we coordinate with the existing psychiatrist rather than replacing that care.

For most bipolar II patients on lamotrigine, we proceed with standard at-home ketamine onboarding plus a continued mood stabilizer. For some bipolar I patients we may recommend a closer-monitored setting initially with a possible step-down to at-home once we see how you respond.

Epilepsy on lamotrigine: a shorter conversation

If you're on lamotrigine for seizure control, the at-home ketamine conversation is generally shorter and more reassuring. Three things matter:

Ketamine at therapeutic at-home doses does not lower seizure threshold. The Shehata 2024 systematic review (PMID 38293492) of 30 studies on ketamine and seizure threshold found 26 supporting an antiepileptic profile and only 4 suggesting pro-epileptic effects, and the pro-epileptic findings were mostly in procedural-sedation contexts at anesthetic doses, not at the antidepressant doses we use. Combining at-home sublingual ketamine with seizure-controlled lamotrigine does not compound seizure risk.

Continuing lamotrigine without interruption is essential. Lamotrigine has one of the more challenging tapering profiles among antiepileptics because abrupt discontinuation can precipitate seizures. There is no scenario where we ask an epilepsy patient to interrupt lamotrigine to access ketamine.

Coordination with the prescribing neurologist is important so they know you're starting ketamine and can flag any seizure-related concerns specific to your individual picture.

Most epilepsy patients on stable lamotrigine for at least 6 months with no recent seizures are good at-home ketamine candidates if the underlying indication (depression, anxiety, PTSD) qualifies.

Unipolar TRD on lamotrigine augmentation: routine

If your psychiatrist added lamotrigine as an augmentation strategy to treat unipolar depression that hadn't responded to first- or second-line treatments, the ketamine intake conversation is essentially the same as any TRD patient's. The Santucci 2025 real-world cohort study (which was specifically in unipolar depression patients) found no attenuation of ketamine outcomes when patients were also on lamotrigine. We proceed with standard onboarding.

What we do at intake

For any patient on lamotrigine, intake includes:

The indication (bipolar I, II, schizoaffective, epilepsy, unipolar TRD augmentation, or other). This is the single most important question because it shapes everything else.

Current dose and how long you've been at that dose. Most lamotrigine dosing for mood stabilization is 100-200 mg/day; for epilepsy it can be higher. Stable dose for at least 8-12 weeks is the most common picture.

Any recent seizures (if epilepsy) or mood episodes (if bipolar). Recent breakthroughs in either category are flags for additional conversation, not automatic contraindications.

Your prescribing physician relationship (psychiatrist or neurologist). We coordinate appropriately and ask for a release of information.

Whether you've had any prior experience with ketamine. Patients who have done ketamine before while on lamotrigine often have useful personal information about whether they noticed any change in the experience.

Bottom line

Lamotrigine and ketamine combine safely. There is no documented pharmacologic interaction that warrants stopping lamotrigine, and the most recent real-world clinical data (Santucci et al. 2025, N=347 including 57 on lamotrigine) found no evidence that lamotrigine attenuates ketamine outcomes in depression patients. The case-by-case verdict reflects the fact that lamotrigine signals different patient contexts (bipolar depression, epilepsy, or unipolar TRD augmentation), each with a slightly different intake conversation, rather than concern about the combination itself. Standard practice is to continue lamotrigine throughout your ketamine course; the attenuation hypothesis from older pretreatment studies in healthy volunteers has not translated into clinically meaningful effects in actual depression patients.